Acadia Pharmaceuticals reported $5M in Cost of Sales for its second fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US $ 5M 1M
Alexion Pharmaceuticals ALXN:US $ 144.9M 33.2M
Alnylam Pharmaceuticals ALNY:US $ 21.8M 1.87M
Biogen BIIB:US $ 449.1M 38M
Biomarin Pharmaceutical BMRN:US $ 97.97M 13.41M
Bristol Myers Squibb BMY:US $ 2675M 978M
Corcept Therapeutics CORT:US $ 1M 0M
Eisai 4523:JP Y 38282M 10227M
Eli Lilly And LLY:US $ 1222M 6.9M
Gw Pharmaceuticals GWPH:US $ 7.64M 1.07M
Intercept Pharmaceuticals ICPT:US $ 1.88M 1.02M
Johnson & Johnson JNJ:US $ 6940M 383M
Neurocrine Biosciences NBIX:US $ 2M 0M
Pfizer PFE:US $ 2232M 114M
Ptc Therapeutics PTCT:US $ 5.3M 1.22M
Sarepta Therapeutics SRPT:US $ 13M 1M
Seattle Genetics SGEN:US $ 78.3M 30.05M
Ultragenyx Pharmaceutical RARE:US $ 1.8M 5.31M
Vanda Pharmaceuticals VNDA:US $ 5.85M 0.64M
Vertex Pharmaceuticals VRTX:US $ 184.52M 22.02M
YTE INCY:US $ 27.96M 6.04M